Kyprolis in trouble. Onyx reps to be fired!

Quote

anonymous

Guest
expert confirmed that triplet regimens are the standard now and that Velcade’s efficacy and pricing mean it will be difficult to replace as the first line treatment. However, it is generally only a matter of time before patient progress as the effectiveness of Velcade-containing regimens diminishes. As a second or third-line treatment, our expert confirmed he has been using Ninlaro more than expected, particularly since gastrointestinal problems appear to have been resolved with the new formulation of the drug.

- Velcade will still be first line, not Kyprolis
- Ninlaro and Kyprolis will split 2nd line and if Ninlaro studies show better data, Kyprolis share will decline

All leftover Onyx reps will be fired and replaced by the OBU
 






anonymous said:
expert confirmed that triplet regimens are the standard now and that Velcade’s efficacy and pricing mean it will be difficult to replace as the first line treatment. However, it is generally only a matter of time before patient progress as the effectiveness of Velcade-containing regimens diminishes. As a second or third-line treatment, our expert confirmed he has been using Ninlaro more than expected, particularly since gastrointestinal problems appear to have been resolved with the new formulation of the drug.

- Velcade will still be first line, not Kyprolis
- Ninlaro and Kyprolis will split 2nd line and if Ninlaro studies show better data, Kyprolis share will decline

All leftover Onyx reps will be fired and replaced by the OBU
Click to expand...

Who said this? Probably a Velcade speaker? Kyprolis is a much better drug and it will get first line after the phase 3 trial comes out.

Kyprolis is doing fine but the goals are too aggressive. 23% growth in one quarter? Actually in one 6 month semester. Still crazy quotas
 


anonymous said:
Who said this? Probably a Velcade speaker? Kyprolis is a much better drug and it will get first line after the phase 3 trial comes out.

Kyprolis is doing fine but the goals are too aggressive. 23% growth in one quarter? Actually in one 6 month semester. Still crazy quotas
Click to expand...

Morgan Stanley Biotech Analyst
 






Maybe that analyst needs to look at the Ninlaro FDA study information. The drug did not even meet it's PFS endpoint. The drug is just an oral Velcade without endpoint data. Kyprolis is the best!!!!!!
 






anonymous said:
Maybe that analyst needs to look at the Ninlaro FDA study information. The drug did not even meet it's PFS endpoint. The drug is just an oral Velcade without endpoint data. Kyprolis is the best!!!!!!
Click to expand...

I don't think Ninlaro is doing that well? At least in my urban centered territory. Maybe in the rural communities for convenience?
 


Funny thing is it looks like Amgen is forcing onyx out. They "forecasting" for S1 is off and they are blaming the reps? Please a 23% increase is crazy. 20% maybe but 23%? Where did they get that number?
 






anonymous said:
Sad thing is now they are hurting their own Amgen reps because a lot of them switched over
Click to expand...

The Amgen reps will not be hurt they will rise and be awesome.

Amgen reps better than Moronyx reps. Onyx no welcome here.

Jim Hassard, Rhonda Farnum, Michael Ehrman, Sebastien Meyer, Richard Paulson, Jeff Ludwig and the great Eric Jensen all approve of Onyx being gone. OBU will right this ship!
 


anonymous said:
Funny thing is it looks like Amgen is forcing onyx out. They "forecasting" for S1 is off and they are blaming the reps? Please a 23% increase is crazy. 20% maybe but 23%? Where did they get that number?
Click to expand...

The forecasting is off because the forecast lead, Greenblatt doesn't know what the kcuf he is doing. Since the US launch by Onyx, this clown hasn't delivered an accurate forecast. He did the same on Blyncyto. Word around TO is he couldn't even forecast a rain shower even when the drops are 2 feet in front of him.

He came out of Onyx and Genentech -- has loser written all over him!
 


anonymous said:
The Amgen reps will not be hurt they will rise and be awesome.

Amgen reps better than Moronyx reps. Onyx no welcome here.

Jim Hassard, Rhonda Farnum, Michael Ehrman, Sebastien Meyer, Richard Paulson, Jeff Ludwig and the great Eric Jensen all approve of Onyx being gone. OBU will right this ship!
Click to expand...

Hey stupid! Don't you know that Farnum and Ehrman both came from Onyx. Wow, you really do live on your planet!
 


So tell me wise ones --

With leaders like RP and RF calling the shots, ME leading the troops, BG pulling the forecast out of his backside, JL and his merry band of misfits in business analytics informing strategy, the future is not bright. NO OFFENSE, but I worked with JH and SM and they aren't any better. The future is not bright!

You can continue to be playground bullies and have a hissy fit about Onyx Reps who are just trying to feed their families like you. Why not recognize that the real blame for KYPROLIS failings comes out of TO and the poor leadership exhibited by those in the castle.

In the meantime, your best and brightest have fled Amgen Country -- BA to Juno, MS to SeaGen, and others to real oncology powerhouses, Genentech, Novartis, Celgene, JNJ, BMS, Lilly, Takeda, AZ, & Merck (all companies with Oncology revenues greater than AMGEN).

ISN'T IT TIME TO:
  • STOP DRINKING THE KOOL-AID?
  • RECOGNIZE THAT THE LEADERSHIP TEAM IS THE PROBLEM?
  • FLEE!
  • CONTROL YOUR OWN DESTINY AND GET THE HECK OUT OF THIS DINOSAUR?
  • LISTEN TO YOUR THERAPIST OR EVEN THAT LITTLE VOICE IN YOU HEAD THAT IS TELLING YOU THE OBVIOUS -- AMGEN IS...
    - THE TITANIC
    - THAT DYING STAR SUCKED INTO THE BLACK HOLE
    - GOING THE WAY OF THE CAVEMAN, THE DINOSAUR AND THE DODO
    - NOT GOOD FOR YOU, YOUR SPOUSE/PARTNER, YOUR CHILDREN, YOUR DOG, CAT, GOLDFISH, PARROT AND OTHER LIVING THINGS
    - YOUR FUTURE!!!!!!!!!!!!!!
 


Reality said:
So tell me wise ones --

With leaders like RP and RF calling the shots, ME leading the troops, BG pulling the forecast out of his backside, JL and his merry band of misfits in business analytics informing strategy, the future is not bright. NO OFFENSE, but I worked with JH and SM and they aren't any better. The future is not bright!

You can continue to be playground bullies and have a hissy fit about Onyx Reps who are just trying to feed their families like you. Why not recognize that the real blame for KYPROLIS failings comes out of TO and the poor leadership exhibited by those in the castle.

In the meantime, your best and brightest have fled Amgen Country -- BA to Juno, MS to SeaGen, and others to real oncology powerhouses, Genentech, Novartis, Celgene, JNJ, BMS, Lilly, Takeda, AZ, & Merck (all companies with Oncology revenues greater than AMGEN).

ISN'T IT TIME TO:
  • STOP DRINKING THE KOOL-AID?
  • RECOGNIZE THAT THE LEADERSHIP TEAM IS THE PROBLEM?
  • FLEE!
  • CONTROL YOUR OWN DESTINY AND GET THE HECK OUT OF THIS DINOSAUR?
  • LISTEN TO YOUR THERAPIST OR EVEN THAT LITTLE VOICE IN YOU HEAD THAT IS TELLING YOU THE OBVIOUS -- AMGEN IS...
    - THE TITANIC
    - THAT DYING STAR SUCKED INTO THE BLACK HOLE
    - GOING THE WAY OF THE CAVEMAN, THE DINOSAUR AND THE DODO
    - NOT GOOD FOR YOU, YOUR SPOUSE/PARTNER, YOUR CHILDREN, YOUR DOG, CAT, GOLDFISH, PARROT AND OTHER LIVING THINGS
    - YOUR FUTURE!!!!!!!!!!!!!!
Click to expand...


You Amgen folks don't get the only commercial leaders from Onyx who came to Amgen were recent hires. The true Onyx talent who were hired in 2012 at the latest or before have all left or never made the transition.

The best of Onyx is now spread throughout the Bay.
 





Write your reply...
Top Bottom
Back
Quote